Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Katzenstein

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
The Journal of Infectious Diseases|August 5, 2003
Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patientsMark A Winters, Ronald J Bosch, Mary A Albrecht, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 19, 2009
Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysisEran Bendavid, Robin Wood, David A Katzenstein, et al.
The Journal of Infectious Diseases|June 16, 2007
More on the treatment-tropism relationship: the impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175Nancy S Shulman, Seble G Kassaye, Mark A Winters, et al.
Future Virology|July 24, 2012
Global analysis of sequence diversity within HIV-1 subtypes across geographic regionsAustin Huang, Joseph W Hogan, Sorin Istrail, et al.
AIDS (London, England)|March 28, 2003
Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugsDavid A Katzenstein, Ronald J Bosch, Nicholas Hellmann, et al.
Journal of Virology|June 14, 2003
High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatmentElizabeth R Johnston, Lynn S Zijenah, Solomon Mutetwa, et al.
AIDS (London, England)|August 19, 2004
Genetic correlates of efavirenz hypersusceptibilityNancy S Shulman, Ronald J Bosch, John W Mellors, et al.
Antimicrobial Agents and Chemotherapy|June 6, 2012
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirineMaya Balamane, Vici Varghese, George L Melikian, et al.
AIDS Patient Care and Stds|March 10, 2004
Infant feeding practices of HIV-infected and uninfected women in ZimbabweDanielle Gottlieb, Avinash K Shetty, Ratidzai M Mapfungautsi, et al.
AIDS (London, England)|October 23, 2003
Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenzRonald J Bosch, Gerald F Downey, David A Katzenstein, et al.
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
The Journal of Infectious Diseases|August 5, 2003
Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patientsMark A Winters, Ronald J Bosch, Mary A Albrecht, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 19, 2009
Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysisEran Bendavid, Robin Wood, David A Katzenstein, et al.
The Journal of Infectious Diseases|June 16, 2007
More on the treatment-tropism relationship: the impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175Nancy S Shulman, Seble G Kassaye, Mark A Winters, et al.
Future Virology|July 24, 2012
Global analysis of sequence diversity within HIV-1 subtypes across geographic regionsAustin Huang, Joseph W Hogan, Sorin Istrail, et al.
AIDS (London, England)|March 28, 2003
Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugsDavid A Katzenstein, Ronald J Bosch, Nicholas Hellmann, et al.
Journal of Virology|June 14, 2003
High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatmentElizabeth R Johnston, Lynn S Zijenah, Solomon Mutetwa, et al.
AIDS (London, England)|August 19, 2004
Genetic correlates of efavirenz hypersusceptibilityNancy S Shulman, Ronald J Bosch, John W Mellors, et al.
Antimicrobial Agents and Chemotherapy|June 6, 2012
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirineMaya Balamane, Vici Varghese, George L Melikian, et al.
AIDS Patient Care and Stds|March 10, 2004
Infant feeding practices of HIV-infected and uninfected women in ZimbabweDanielle Gottlieb, Avinash K Shetty, Ratidzai M Mapfungautsi, et al.
AIDS (London, England)|October 23, 2003
Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenzRonald J Bosch, Gerald F Downey, David A Katzenstein, et al.
Pageof 6